Gastroesophageal Junction Cancer News

News

Nivolumab Added to Trastuzumab and FOLFOX Improved Survival and Response Among Patients with ERBB2-Positive Gastroesophageal Adenocarcinoma

07/13/2022

Allison Casey ;

According to results from a phase 2 trial, the addition of nivolumab to trastuzumab and chemotherapy in the first-line setting for patients with ERBB2-positive gastric and gastroesophageal junction adenocarcinoma improved progression-free and...

According to results from a...

07/13/2022

Oncology

News

No Survival Benefit in Adding Napabucasin to Paclitaxel for Advanced Gastric, GEJ Cancers

06/16/2022

Allison Casey ;

Final results from the phase 3 BRIGHTER trial showed that adding napabucasin to paclitaxel therapy offered no overall survival benefit for pretreated patients with advanced gastric or gastroesophageal junction cancers.

Final results from the phase 3...

06/16/2022

Oncology

News

Trifluridine Plus Tipiracil Improves Survival for Patients With Metastatic Gastric, GEJ Cancers Regardless of Age

06/16/2022

Allison Casey ;

Results from a recent subgroup analysis of the phase 3 TAGS trial showed that trifluridine plus tipiracil is a safe and effective treatment option for previously treated patients of all age groups with metastatic gastric or gastroesophageal...

Results from a recent subgroup...

06/16/2022

Oncology

News

Trastuzumab Deruxtecan Superior to Chemo for HER2+ Gastric Cancer, GEJ Adenocarcinoma

02/03/2022

The phase 2 DESTINY-Gastric01 trial reveal trastuzumab deruxtecan provides a statistically significant benefit versus standard chemotherapy in patients with HER2-positive advanced gastric cancer or GEJ adenocarcinoma.

The phase 2 DESTINY-Gastric01...

02/03/2022

Oncology

Conference Insider

Second-Line Triplet Combo Shows Promise in Patients With HER2+ Advanced GI/GEJ Cancer

06/02/2021

Hina M. Porcelli ;

According to Sun Young Rha, MD, PhD, et al, second-line trastuzumab plus ramucirumab and paclitaxel showed promising activity and manageable safety in a study of patients with HER2+ GI/GEJ cancer.

According to Sun Young Rha, MD,...

06/02/2021

Oncology

News

FDA Approves Pembrolizumab for Advanced Esophageal and GEJ Carcinoma Treatment

03/24/2021

The FDA has approved pembrolizumab for the treatment of patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) carcinoma.

The FDA has approved...

03/24/2021

Oncology

News

Apexigen`s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

10/15/2020

The FDA granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer.

The FDA granted orphan drug...

10/15/2020

IO Learning

News

No Benefit With Trastuzumab Beyond Progression for HER2-Positive Gastric, GEJ Cancer

04/30/2020

Adding trastuzumab to paclitaxel did not significantly improve survival or responses in patients with HER2-positive advanced gastric or GEJ cancer in the T-ACT study.

Adding trastuzumab to paclitaxel...

04/30/2020

Oncology

News

FDA Approves Cyramza for Advanced Stomach Cancer or Gastroesophageal Junction Adenocarcinoma

04/22/2014

The FDA approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma.

The FDA approved Cyramza...

04/22/2014

First Report Managed Care

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology